Mark Cuban Cost Plus Drug Company, PBC
Dallas, TX
- UEI
- N8P7MQ937WN7
- CAGE
- 9VYL8
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3015 Taylor St, Dallas, TX 75226, USA
- Website
- markcubancostplusdrugcompany.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $1,393,259 |
| FY2025 | $205,920 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of the Army | $1,393,259 |
Contract awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Fagron Sterile Services | Wichita, KS | 325412 Pharmaceutical Preparation Manufacturing |
| Wells Pharma Of Houston LLC | Houston, TX | 325412 Pharmaceutical Preparation Manufacturing |
| Quva Pharma, Inc. | Sugar Land, TX | 325412 Pharmaceutical Preparation Manufacturing |
| Memsel Inc. | Fort Worth, TX | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Mckesson Corporation | Irving, TX | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Mark Cuban Cost Plus Drug Company, PBC, a for-profit pharmaceutical manufacturer based in Dallas, Texas, operates as a prime contractor on federal pharmaceutical research and development contracts under total small business set-asides, with no subcontract footprint. The company holds a three-award prime portfolio valued at $16.1 million across the Department of Defense and the Department of the Army, all dollars obligated.
Mark Cuban Cost Plus Drug Company serves three distinct DoD customer components. The Defense Advanced Research Projects Agency anchors the portfolio with a $14.5 million multiple-award Other Transaction Indefinite Delivery Vehicle, awarded August 9, 2024, supporting Phase 1 of the EQUIP-A-PHARMA (Ultra-Rapid Manufacturing of Pharmaceuticals) program — a research, development, and demonstration effort to accelerate generic and biosimilar pharmaceutical manufacturing within Abbreviated New Drug Application standards. The Department of the Army's Joint PEO Chemical and Biological Defense awarded a $1.393 million definitive contract on April 13, 2026, under total small business set-aside for generation of a chemistry, manufacturing, and controls (CMC) data package suitable for FDA ANDA submission, with performance in Dallas through April 12, 2028. The Department of the Army Materiel Command's Research Development and Engineering Command issued a $205,920 SBIR Phase I definitive contract on June 16, 2025, for proof-of-concept production of sterile saline and sterile water using nonsterile source water under current good manufacturing practice regulations, with completion scheduled for December 15, 2025.
Activity has been episodic — one award per year across 2024, 2025, and 2026 — with one award ($1.4 million) facing ultimate completion inside the next twenty-four months and therefore subject to recompete. Mark Cuban Cost Plus Drug Company's capability footprint centers on pharmaceutical manufacturing process development, CMC data generation, sterile drug substance production, and advanced manufacturing methodologies aligned with FDA regulatory standards. The vendor competes exclusively under total small business set-asides on all three awards, with no vehicle holdings or sub-award activity in the source record.
Quick answers
Is Mark Cuban Cost Plus Drug Company, PBC registered in SAM.gov?
Yes. Mark Cuban Cost Plus Drug Company, PBC's SAM.gov registration is active through January 31, 2027.
How much has Mark Cuban Cost Plus Drug Company, PBC received in federal contracts?
Federal contracts obligated $205,920 to Mark Cuban Cost Plus Drug Company, PBC in fiscal year 2025 and $1,599,179 in fiscal years 2023 through 2027.
How does Mark Cuban Cost Plus Drug Company, PBC rank among federal contractors?
Mark Cuban Cost Plus Drug Company, PBC ranked #86 in PSC AN13 in FY2025.
What is Mark Cuban Cost Plus Drug Company, PBC's most recent federal award?
Mark Cuban Cost Plus Drug Company, PBC's most recent federal contract award is Mark cuban cost plus drug company (mccpdc) intends to generate a chemistry, manufacturing, and controls (CMC) data… (W911SR26CA011), from ACC Aberdeen Proving Ground, on April 13, 2026.
On GovTribe
See Mark Cuban Cost Plus Drug Company, PBC's full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors